We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: VA-ECMO
MedXY News
EnglishTag

VA-ECMO

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT
Cardiologycardiogenic shockoxygenation

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY|Dec 12, 2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarker

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock
Cardiologybleedingcardiogenic shock

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

By MedXY|Dec 9, 2025

A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infar

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial
Cardiologycardiogenic shockVA-ECMO

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

By MedXY|Dec 9, 2025

In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.

Long-Term Functional Recovery and Survival after VA-ECMO: Insights from a 26-Center Prospective Cohort Study
Cardiologycritical carefunctional recovery

Long-Term Functional Recovery and Survival after VA-ECMO: Insights from a 26-Center Prospective Cohort Study

By MedXY|Oct 3, 2025

A multicenter study reveals that 30% of adult VA-ECMO patients survive 12 months without new disability, with most disability developing within the first 6 months. Functional independence and employment improve by 12 months post-ECMO.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities